SCHEMBL3726447

SCHEMBL3726447

COc1cc(-c2nc3ccccn3c2-c2ccnc(Nc3ccc(N4CCC(N(C)C)CC4)cc3)n2)ccc1OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 9/20 0.50
EGFR P00533 9/20 0.49
ERBB2 P04626 9/20 0.49
INSR P06213 9/20 0.49
MAPK14 Q16539 2/20 0.48
CDK19 Q9BWU1 3/20 0.47
ALK Q9UM73 2/20 0.47
PLK4 O00444 1/20 0.47
CHEK1 O14757 1/20 0.47
AURKA O14965 1/20 0.47
DAPK3 O43293 1/20 0.47
ROCK2 O75116 1/20 0.47
PRKD3 O94806 1/20 0.47
MAP4K4 O95819 1/20 0.47
PAK4 O96013 1/20 0.47
CHEK2 O96017 1/20 0.47
NTRK1 P04629 1/20 0.47
PRKCG P05129 1/20 0.47
LCK P06239 1/20 0.47
FYN P06241 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3718815 0.93 IGF1R (0.58) IGF1REGFRERBB2INSRMAPK14
SCHEMBL3761939 0.88 EGFR (0.49) IGF1REGFRERBB2INSRMAPK14
SCHEMBL3761942 0.88 EGFR (0.49) IGF1REGFRERBB2INSRMAPK14
SCHEMBL15899571 0.87 EGFR (0.54) IGF1REGFRERBB2INSRMAPK14
SCHEMBL3766695 0.87 EGFR (0.54) IGF1REGFRERBB2INSRMAPK14
SCHEMBL3772445 0.85 IGF1R (0.59) IGF1REGFRERBB2INSRMAPK14
SCHEMBL3725890 0.84 CDK19 (0.64) IGF1REGFRERBB2INSRCDK19
SCHEMBL3771297 0.84 IGF1R (0.56) IGF1REGFRERBB2INSRCDK19
SCHEMBL3767755 0.84 IGF1R (0.59) IGF1REGFRERBB2INSRMAPK14
SCHEMBL3767669 0.84 IGF1R (0.67) IGF1REGFRERBB2INSRMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2435436-B1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBVIE INC (US) 2014-07-30 EP claimed
US-8354422-B2 Pyrimidine inhibitors of kinase activity ABBOTT LABORATORIES INC. (US) 2013-01-15 US claimed
WO-2010138576-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 WO claimed
US-20100305126-A1 Pyrimidine Inhibitors of Kinase Activity ABBOTT LABORATORIES (US) 2010-12-02 US claimed
EP-2435436-B1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBVIE INC (US) 2014-07-30 EP disclosed
US-8354422-B2 Pyrimidine inhibitors of kinase activity ABBOTT LABORATORIES INC. (US) 2013-01-15 US disclosed
WO-2010138576-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 WO disclosed
US-20100305126-A1 Pyrimidine Inhibitors of Kinase Activity ABBOTT LABORATORIES (US) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305126-A1 Pyrimidine Inhibitors of Kinase Activity IGF1R, CDK2, TK1 IGF1R 1/4885EGFR 328/4885ERBB2 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.